Turnstone Biologics Corp. Common Stock(TSBX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) (2836)
- Exchange
- XNAS
- Market Cap
- $0.0B
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes…
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -6.30% | 2 |
| Feb | +26.86% | 2 |
| Mar | -14.39% | 2 |
| Apr | -3.06% | 2 |
| May | -1.63% | 2 |
| Jun | +10.11% | 2 |
| Jul | -0.11% | 3 |
| Aug | -28.95% | 3 |
| Sep | -40.67% | 2 |
| Oct | -30.87% | 2 |
| Nov | -11.18% | 2 |
| Dec | +7.58% | 2 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.41
- Correlation (SPY)
- 8.6%
- R²
- 0.01
- Ann. Volatility
- 49.0%
- SPY Volatility
- 10.3%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-08-12 | OrbiMed Capital GP VI LLC | Director | U | −6,198,530 | — | EDGAR | |
| 2025-08-12 | Versant Ventures V, LLC | 10%+ Owner | U | −33,816,920 | — | EDGAR | |
| 2025-08-08 | Rishi Gupta | Director | U | −3,099,265 | — | EDGAR | |
| 2025-08-08 | Davis Jerel | Director | U | −3,381,692 | — | EDGAR | |
| 2024-07-02 | Kanya Rajangam | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-07-02 | William D. Waddill | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-07-02 | Robert J Gould | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-07-02 | Davis Jerel | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-07-02 | Rishi Gupta | Director | Grant (A) | +12,770 opt | — | EDGAR | |
| 2024-04-16 | William D. Waddill | Director | Grant (A) | +25,540 opt | — | EDGAR | |
| 2024-01-11 | FMR LLC | — | — | — | EDGAR | ||
| 2023-10-17 | Venkat Ramanan | Chief Financial Officer | Grant (A) | +46,606 opt | — | EDGAR | |
| 2023-10-17 | Rishi Gupta | Director | Grant (A) | +25,540 opt | — | EDGAR | |
| 2023-10-17 | Peter Joseph Jr. Campisi | Chief Legal Officer | Grant (A) | +44,377 opt | — | EDGAR | |
| 2023-10-17 | STEWART ABBOT | Chief Scientific Officer | Grant (A) | +45,542 opt | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | Director | 2,682,599 | $952.3K | $10.00M | 1 | 2023-07-24 |
| 2 | FMR LLC | 10%+ Owner | 296,396 | $105.2K | $0 | 2 | 2024-01-11 |
| 3 | Versant Ventures V GP-GP (Canada), Inc. | 10%+ Owner | 90,888 | $32.3K | $27.00M | 1 | 2023-07-27 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.